Recent News

• 03.31.2025 - Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update
• 03.05.2025 - Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation Study
• 02.03.2025 - Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
• 01.22.2025 - Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
• 01.21.2025 - Phio Pharmaceuticals Announces Closing of $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
• 01.21.2025 - Phio Pharmaceuticals Announces Closing of $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Recent Filings

• 03.04.2025 - 3 Initial statement of beneficial ownership of securities
• 02.20.2025 - EX-99.1 EX-99.1
• 02.20.2025 - 8-K Current report
• 02.07.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 01.29.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 01.28.2025 - EFFECT Notice of Effectiveness
• 01.28.2025 - D Notice of Exempt Offering of Securities
• 01.28.2025 - D Notice of Exempt Offering of Securities
• 01.28.2025 - D Notice of Exempt Offering of Securities
• 01.27.2025 - CORRESP Correspondence